Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy

Trotti, Andy; Byhardt, Roger W.; Stetz, JoAnn; Gwede, Clement K.; Corn, Benjamin W.; Fu, Karen K.; Gunderson, Leonard L.; McCormick, Beryl; Morris, Mitchell; Rich, Tyvin A.; Shipley, William U.; Curran, Walter J.

doi:10.1016/s0360-3016(99)00559-3

Cited by 730 publications

(420 citation statements)

References 3 publications

Supporting

Mentioning

401

Contrasting

Unclassified

Order By: Relevance

“…9,10 Survival rates were referenced from the end of Re-RT and were calculated with the Kaplan-Meier method. 11 The difference between the Kaplan-Meier curves was assessed in a univariate manner with the log-rank test.…”

Section: Methodsmentioning

confidence: 99%

Prognostic factors for functional outcome and survival after reirradiation for in‐field recurrences of metastatic spinal cord compression

Rades

Rudat

Veninga

et al. 2008

Cancer

View full text Add to dashboard Cite

Objective: We examined whether glucose transporter 1 (GLUT1) deficiency causes common idiopathic generalized epilepsies (IGEs). Methods: The IGEs are common, heritable epilepsies that usually follow complex inheritance; currently little is known about their genetic architecture. Previously considered rare, GLUT1 deficiency, due to mutations in SLC2A1, leads to failure of glucose transport across the blood–brain barrier and inadequate glucose for brain metabolism. GLUT1 deficiency was first associated with an encephalopathy and more recently found in rare dominant families with epilepsy and paroxysmal exertional dyskinesia (PED). Five hundred four probands with IGEs and 470 controls underwent SLC2A1 sequencing. Glucose transport was assayed following expression of SLC2A1 variants in Xenopus oocytes. All available relatives were phenotyped, and SLC2A1 was sequenced. Results: Functionally validated mutations in SLC2A1 were present in 7 of 504 (1.4%) probands and 0 of 470 controls. PED, undiagnosed prior to study, occurred in 1 proband and 3 of 13 relatives with mutations. The IGEs in probands and relatives were indistinguishable from typical IGE. Three cases (0.6%) had mutations of large functional effect and showed autosomal dominant inheritance or were de novo. Four (0.8%) cases had a subtle functional effect; 2 showed possible dominant inheritance, and 2 did not. These alleles leading to subtle functional impairment may contribute to complex, polygenic inheritance of IGE. Interpretation: SLC2A1 mutations contribute to approximately 1% of IGE both as a dominant gene and as a susceptibility allele in complex inheritance. Diagnosis of GLUT1 deficiency has important treatment (ketogenic diet) and genetic counseling implications. The mechanism of restricted glucose delivery differs from the current focus on IGEs as ion channel disorders. ANN NEUROL 2012;72:807–815

show abstract

Section: Methodsmentioning

confidence: 99%

Prognostic factors for functional outcome and survival after reirradiation for in‐field recurrences of metastatic spinal cord compression

Rades

Rudat

Veninga

et al. 2008

Cancer

View full text Add to dashboard Cite

show abstract

“…All patients who received at least one cycle were evaluable for toxicity. Toxicity was evaluated according to the National Cancer Institute-Common Toxicity Criteria (version 2.0) [19].…”

Section: Baseline and Follow-up Assessmentsmentioning

confidence: 99%

Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer

Xenidis

Vardakis

Varthalitis

et al. 2010

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

“…Toxicities were evaluated with respect to incidence and severity using National Cancer Institute common toxicity criteria (NCI-CTC, version 2.0) (Trotti et al, 2000).…”

Section: Response and Toxicity Evaluationmentioning

confidence: 99%

Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study

et al. 2005

View full text Add to dashboard Cite

The purpose of this study was to determine whether docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma. Chemotherapy-naïve or previously treated patients (one regimen) with histopathologically documented endometrial carcinoma and Eastern Cooperative Oncology Group performance status p2 entered the study. Docetaxel 70 mg m À2 was administered intravenously on day 1 of a 3-week cycle up to a maximum of six cycles. If patients responded well to docetaxel, additional cycles were administered until progressive disease or unacceptable toxicity occurred. Of 33 patients with a median age of 59 years (range, 39 -74 years) who entered the study, 14 patients (42%) had received one prior chemotherapy regimen. In all, 32 patients were evaluable for efficacy, yielding an overall response rate of 31% (95% confidence interval, 16.1 -50.0%); complete response and partial response (PR) were 3 and 28%, respectively. Of 13 pretreated patients, three (23%) had a PR. The median duration of response was 1.8 months. The median time to progression was 3.9 months. The predominant toxicity was grade 3 -4 neutropenia, occurring in 94% of the patients, although febrile neutropenia arose in 9% of the patients. Oedema was mild and infrequent. Docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma, including those previously treated with chemotherapy; however, the effect was transient and accompanied by pronounced neutropenia in most patients.

show abstract

Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy

Cited by 730 publications

References 3 publications

Prognostic factors for functional outcome and survival after reirradiation for in‐field recurrences of metastatic spinal cord compression

Prognostic factors for functional outcome and survival after reirradiation for in‐field recurrences of metastatic spinal cord compression

Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer

Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study

Contact Info

Product

Resources

About